I think SGLB will change the metal 3DP landscape. I hate
I think SGLB will change the metal 3DP landscape. I hate trying to put meaning behind something that is not specifically stated, but I find the notes by GE Aviation very interesting. I'm particularly interesting when Prabhjot Singh has anything to say because he's the scientific mind that runs GE AM at Global Research.
Prabhjot Singh... “We have a very strong materials and manufacturing group ,” Singh says. “It is helping us bring in new technology and mature it to our needs. The engineering teams we work with keep us real, and they help us develop the right kinds of technology .”
Another individual is Christine Furstross, GE Global Research Tech Dir...“We’re just learning what gives the materials the types of properties it’s achieving,” she said. “What are the things we can do in the equipment to make sure we make a material strong enough and tough enough? How do we make sure we do that every time for every part?”
http://www.deskeng.com/articles/aabndb.htm
Read what Christine Furstoss has to say about metal AM, quality, and strategic partners:
I would say that there are four factors that will truly enable Additive Manufacturing to incorporate more types of materials and more types of parts. For simplicity I’ll limit the discussion to looking at extending AM to metallic parts. As I mentioned, what’s exciting and also a challenge is that we are building up material properties at the same time we are building the geometry or the form. But, the software and the predictability of outcomes to be able to do that on a large scale just aren’t quite ready. And that’s not a surprise. In the casting industry and the forging industry it has taken decades to really be able to predict how a process leads directly to the properties you get out of the material. We are really just at the birth of that with AM. But I think with all the advances in high performance computing and a dramatic increase in the number of simulations that we can look at, we shouldn’t take decades anymore. But it is not going to be a simple path. So, that’s one of the biggest gaps that we are working on across GE and with our strategic partners.
http://www.americas.gecapital.com/GECA_Docume...l_2013.pdf
Take it as you will. As I mentioned, I don't do this kind of thing where I "read between the lines" often. But the way I interpret it, the technology from Sigma Labs is being utilized by GE in a meaningful way. What has been stated in regards to closed-loop control technology, Sigma Labs has only been the company to offer a solution. That is not to say what I've stated is the final and end-all. If anyone sees otherwise, I'm open to discussion about technology to bring process control to 3DP.
NextTrip Inc. (NTRP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
Top 5 Most Recently Viewed Articles
Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...
Continue Reading
aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...
Continue Reading
Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...
Continue Reading
GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...
Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...
Continue Reading